NEW YORK ( TheStreet) -- Another week into earnings season and Wall Street is still moving at full speed. Here is what to watch on Monday.Vivus (VVUS) Who They Are: Vivus is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. Vivus trades an average of 14.1 million shares per day with a marketcap of $2.2 billion. VVUS data by YCharts
Vivus is forecast to record shallow second-quarter earnings after the market closes July 30. The consensus estimate is currently a loss of 23 cents a share, another drop of three cents from a loss of 20 cents during the equivalent quarter last year. Analyst opinion is mixed with this company. Most of the analysts surveyed don't believe a buy or a sell is currently warranted. Right now, Vivus has five buy recommendations out of 11 analysts covering the company, six holds, and no analysts recommend selling. Four out of 11 analysts now rate Vivus a strong buy down from five analysts a month ago. Compared to three months ago, fewer analysts are rating this company as a strong buy. The stock has appreciated 180% in the last year, and the average analyst target price for Vivus is $38.29. It's not a typo, Vivus really is up 180% and it was on my radar a lot. The last date Vivus released earnings was May 7, and the closing price before earnings was $23.58. Based on Tuesday's closing price of $23, shares are down 2.5%. The bottom line has falling earnings year-over-year with a loss of $46.14 million last fiscal year compared to an even bigger loss of $66.07 million in the previous year. With 15% short interest, investors better know what they are doing before picking this one up -- 15% is the sweet spot for short interest as a bearish indicator. I like what they do as a company, but I would avoid the stock as an investment at this level. The earnings release may not have much of an impact either way because of the binary reaction pharmaceuticals have to trial results.
Float Short: 7.30% MAS Earnings Per Share data by YCharts
Masco is anticipated to report good second-quarter earnings after the market closes on July 30. The consensus estimate is currently 11 cents a share, an improvement of 6 cents (54.5%) from 5 cents during the same period last year. Analyst opinion is mixed with this company. Most of the analysts surveyed don't believe a buy or a sell should be made at this point. Right now, Masco has two buy recommendations out of 13 analysts covering the company, nine holds, and two recommend selling. The stock has appreciated 21.5 % in the last year, and the average analyst target price for Masco is $13.88. In the previous earnings release on April 30, the closing price before earnings was $13.18. In comparison to a recent price of $13.63, shares are down 4.8%. For the same fiscal period year-over-year, revenue has declined to $7.47 billion last fiscal year compared to $7.49 billion in the previous year. The bottom line has lower losses year-over-year of $578 million last fiscal year compared to a loss of $1.05 billion in the previous year. The company's earnings before interest and taxes are rising with an EBIT year-over-year loss of $295 million for the last fiscal year vs. a loss of $463 million for the previous annual report. At the time of publication, the author held no positions in any of the stocks mentioned. This article is commentary by an independent contributor, separate from TheStreet's regular news coverage.